(RTTNews) - Haemonetics Corporation (HAE), a healthcare company, on Thursday revised its fiscal 2026 outlook.
For the full year, the company now expects adjusted income of $4.90 to $5 per share, compared with the prior guidance of $4.80 to $5 per share.
Haemonetics now anticipates its annual revenue to decline 1% to 3%, compared with the earlier expectation for a decline of 1% to 4%.
For fiscal 2025, the company had posted adjusted income of $4.57 per share, with revenue of $1.361 billion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
